Uveal Melanoma

Contrast Agent Distinguishes Solid Tumors From Subretinal Effusion

Published in Cancer Weekly, June 5th, 2001

by Sonia Nichols, senior medical writer - The contrast agent Levovist is somewhat useful for visualizing tumor vascularization in uveal melanoma, but it is more effective for distinguishing solid tumors from subretinal hemorrhage, according to a German study of color Doppler sonography.

Uveal melanoma forms in the uvea, or vascular layer of the eye. Researchers in Berlin at Humboldt University have issued a report of the value of Levovist, a contrast agent, for differentiating tumor-associated blood vessels from normal blood vessels in this particular type of cancer. Their assessment concludes that Levovist adds little value to sonographic imaging for distinguishing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-06-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry